Stryker’s $220 Million Acquisition of HyperBranch Medical Technology, Inc.

Sidley Austin LLP served as outside legal counsel for Stryker in connection with this transaction.

Stryker (NYSE:SYK) executed the acquisition of privately-held HyperBranch Medical Technology, Inc. for a total equity value of approximately $220 million in an all cash transaction. HyperBranch is dedicated to developing medical devices based on its proprietary polymers and cross-linked hydrogels. Its Adherus AutoSpray Dural Sealant product is one of only two FDA-approved dural sealants on the market.

The acquisition of HyperBranch supports our growth strategy within our Neurotechnology business.

Stryker Corporation develops, manufactures, and markets specialty surgical and medical products. The company, led by Kevin A Lobo, Timothy J Scannell and Graham A McLean, in 2017 recorded $12 Billion revenues.

The Sidley deal team was led by corporate partner Seth Katz (Picture)(Chicago) and included employee benefits partner Ben Rosemergy (Chicago); tax partner Suresh Advani (Chicago); FDA partner William McConagha (Washington, D.C.); healthcare partner William Sarraille (Washington, D.C.); real estate partner Elizabeth McCloy (Chicago); environmental partner Heather Palmer (Houston) and corporate associates Brent Steele, Tiffany Chan and Leigh Rorick (Chicago).

Involved fees earner: Seth Katz – Sidley Austin LLP; Brent Steele – Sidley Austin LLP; Tiffany Chan – Sidley Austin LLP; Leigh Rorick – Sidley Austin LLP; Benjamin Rosemergy – Sidley Austin LLP; Suresh Advani – Sidley Austin LLP; William McConagha – Sidley Austin LLP; William Sarraille – Sidley Austin LLP; Elizabeth McCloy – Sidley Austin LLP; Heather Palmer – Sidley Austin LLP;

Law Firms: Sidley Austin LLP;

Clients: Stryker Corporation;

Author: Ambrogio Visconti